<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20260517069427N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2026-10-14</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the Efficacy of Topical Cyclosporine versus Flucort in Patients with Meibomian Gland Dysfunction: A Randomized Clinical Trial.</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the Efficacy of Topical Cyclosporine versus Flucort in Patients with Meibomian Gland Dysfunction: A Randomized Clinical Trial.Results</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2026-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>90</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/93308</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Unit of randomization:
The unit of randomization in this study is the patient. Eligible patients will be randomly assigned to one of the three treatment groups.

Method of sequence generation:
The random allocation sequence will be generated using a random number table. After enrollment, each eligible patient will be assigned to one of the three treatment groups according to the predetermined randomization sequence.

Allocation concealment:
Due to the nature of the interventions, patients will be aware of their assigned treatment and therefore patient blinding will not be performed. However, the researcher/assessor responsible for evaluating and recording the study outcomes will be blinded to the treatment allocation. Patient assignment will be performed according to the randomization table, and the outcome assessor will not be informed of the patients' treatment groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Meibomian Gland Dysfunction (MGD).</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Cyclosporine 0.05% eye drops, one drop every 12 hours in both eyes for 1 months. Intervention 2: Intervention group: Fluocort 0.1% eye drops, one drop every 12 hours in both eyes for 1 month. Intervention 3: Control group: Tearlose artificial tears, one drop every 6 hours in both eyes for 1 month.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Deidentified individual participant data, study protocol, statistical analysis plan, clinical study report, and data dictionary. The shared participant data will include deidentified clinical and outcome data collected during the study.

When:
The data and documents will become available 6 months after publication of the study results and will remain available for 5 years.

To whom:
The deidentified data and study documents will be available to academic researchers and other researchers with a legitimate scientific research purpose

Conditions:
Data may be used for legitimate scientific research, secondary analyses, and systematic reviews. Requests will be reviewed by the research team, and data will only be provided after approval and confirmation of confidentiality.

Where to obtain:
Requests should be submitted to the principal investigator via the contact information provided in the IRCT registration. Approved data and documents will be provided electronically.

How to obtain:
Applicants should submit a written request describing their research purpose and proposed analysis. Requests will be reviewed by the research team. Approved requests will be processed within 30 days.

Comments:
تنها داده‌های غیرقابل شناسایی به اشتراک گذاشته خواهند شد و هیچ‌گونه اطلاعاتی که بتواند به‌طور مستقیم هویت شرکت‌کنندگان را مشخص کند ارائه نخواهد شد.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hossin mohamad rabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti University of Medical Sciences, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4751411498</zip>
        <telephone>+98 21 7762 6550</telephone>
        <email>omide1394@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>hossin mohamd rabi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shahid Beheshti University of Medical Sciences, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>4751411498</zip>
        <telephone>+98 21 7762 6550</telephone>
        <email>omide1394@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>بیماران با سن بالای 18 سال
مبتلا به اختلال عملکرد غدد میبومین با علائم خشکی چشم خفیف تا متوسط</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients who are unwilling to continue participating in the research study
Development of a drug hypersensitivity reaction
Schirmer test result of less than 10 mm over 5 minutes and tear meniscus height of less than 1 mm
History of ocular surgery
History of hormonal medication use
History of contact lens use
History of systemic diseases such as hypertension or diabetes
Presence of blepharitis or treatment for blepharitis within the past 3 months</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Cyclosporine 0.05% eye drops, one drop every 12 hours in both eyes for 1 months.</i_keyword>
      <i_keyword>Intervention group: Fluocort 0.1% eye drops, one drop every 12 hours in both eyes for 1 month</i_keyword>
      <i_keyword>Control group: Tearlose artificial tears, one drop every 6 hours in both eyes for 1 month.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Improvement in dry eye symptoms and signs. Timepoint: Assessment of dry eye symptoms and signs, including the Schirmer test and other clinical parameters, before the start of the study and one month after treatment. Method of measurement: OSDI, Tear Break-Up Time( TBUT), Non-Invasive Tear Break-Up Time(NIBUT), Meibography, Schirmer Test, Ocular Surface Staining.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Changes in Schirmer test; TBUT; NIBUT; corneal staining; meibomian gland area; OSDI score; meibomian gland morphology. Timepoint: One month after treatment, the tests and clinical examinations will be repeated for comparison. Method of measurement: Schirmer test; Tear Break-Up Time (TBUT); Non-Invasive Tear Break-Up Time (NIBUT); corneal staining; meibomian gland area; OSDI score; changes in meibomian gland morphology.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2026-08-27</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Baharestan District, Ibn Sina Street, Torfeh Eye Hospital, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
